Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Cox

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
Journal of Inherited Metabolic Disease|June 19, 2001
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapyF M Platt, M Jeyakumar, U Andersson, et al.
Journal of Inherited Metabolic Disease|May 30, 2008
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringT M Cox, J M F G Aerts, N Belmatoug, et al.
Journal of Inherited Metabolic Disease|November 8, 2003
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statementT M Cox, J M F G Aerts, G Andria, et al.
Nature Genetics|November 5, 1999
Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. The European Haemochromatosis ConsortiumA T Merryweather-Clarke, J J Pointon, J D Shearman, et al.
Science Immunology|September 30, 2021
Immune signatures underlying post-acute COVID-19 lung sequelaeI S Cheon, C Li, Y M Son, et al.
Blood Cells, Molecules & Diseases|March 10, 2017
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher diseaseM Biegstraaten, T M Cox, N Belmatoug, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
Journal of Inherited Metabolic Disease|June 19, 2001
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapyF M Platt, M Jeyakumar, U Andersson, et al.
Journal of Inherited Metabolic Disease|May 30, 2008
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringT M Cox, J M F G Aerts, N Belmatoug, et al.
Journal of Inherited Metabolic Disease|November 8, 2003
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statementT M Cox, J M F G Aerts, G Andria, et al.
Nature Genetics|November 5, 1999
Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. The European Haemochromatosis ConsortiumA T Merryweather-Clarke, J J Pointon, J D Shearman, et al.
Science Immunology|September 30, 2021
Immune signatures underlying post-acute COVID-19 lung sequelaeI S Cheon, C Li, Y M Son, et al.
Blood Cells, Molecules & Diseases|March 10, 2017
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher diseaseM Biegstraaten, T M Cox, N Belmatoug, et al.
Pageof 15